Please assess the completion status of the following clinical trial:

Trial Title: Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male patients aged 6 to 15 years.~* Patients with autism spectrum disorder diagnosed by using DSM-5.~* Patients with average of daily sleep latency persisted over 30 min and the condition is continuous over 3 months~* Patients who are out-patient, not hospitalized patient.~* Signed informed consent obtained from rearer(s)/parent(s)/guardian(s) of the patient, or signed IC or informed assent obtained from the patient themselves.~Exclusion Criteria:~* Patients with at least severity in either Conceptual area, or Social area, or Practical area of intellectual disability have judged more than severe by using DSM-5.~* Patients who took melatonin (including supplement) in history.~* Patients who had taken Ramelteon within 4 weeks before clinical study starts.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- NPC-15 Granules Lower Dose (Type: EXPERIMENTAL): NPC-15 Granules Lower Dose group which is administered 1mg melatonin
- NPC-15 Granules Higher Dose (Type: EXPERIMENTAL): NPC-15 Granules Higher Dose group which is administered 4 mg melatonin
- NPC-15 Placebo Granule (Type: PLACEBO_COMPARATOR): NPC-15 Placebo Granules group which is administered placebo melatonin

Based on this trial design, predict the completion outcome and termination type (if applicable).